Epidemiology of pineoblastoma in the United States, 2000-2017.

epidemiology incidence pineoblastoma survival

Journal

Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528

Informations de publication

Date de publication:
Apr 2022
Historique:
entrez: 4 4 2022
pubmed: 5 4 2022
medline: 5 4 2022
Statut: epublish

Résumé

Pineoblastoma (PB) is a rare malignant brain tumor originating in the pineal gland. Here, we provide a comprehensive epidemiological analysis of PB in the United States from 2000 to 2017. Data on 1133 patients with PB were acquired from the Central Brain Tumor Registry of the United States, in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, from 2000 to 2017. Age-adjusted incidence rates (AAIRs) per 100 000 and incidence rate ratios (IRRs) were reported for age, sex, race, and ethnicity. Using the National Program of Cancer Registries survival database, median survival and hazard ratios (HRs) were evaluated for overall survival from 2001 to 2016. Incidence was highest in ages 0-4 years (AAIR: 0.049, 95% CI: 0.042-0.056), decreasing as age increased. Incidence was higher among patients who are Black compared to patients who are White (IRR: 1.71, 95% CI: 1.48-1.98, PB incidence is highest among children and patients who are Black, and there may be a potential interaction between these factors. Survival is worse among males, young children, and elderly adults, and those who received no surgery. Comprehensive, population-based statistics provide critical information on PB characteristics that could be useful in impacting patient care and prognosis.

Sections du résumé

Background UNASSIGNED
Pineoblastoma (PB) is a rare malignant brain tumor originating in the pineal gland. Here, we provide a comprehensive epidemiological analysis of PB in the United States from 2000 to 2017.
Methods UNASSIGNED
Data on 1133 patients with PB were acquired from the Central Brain Tumor Registry of the United States, in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, from 2000 to 2017. Age-adjusted incidence rates (AAIRs) per 100 000 and incidence rate ratios (IRRs) were reported for age, sex, race, and ethnicity. Using the National Program of Cancer Registries survival database, median survival and hazard ratios (HRs) were evaluated for overall survival from 2001 to 2016.
Results UNASSIGNED
Incidence was highest in ages 0-4 years (AAIR: 0.049, 95% CI: 0.042-0.056), decreasing as age increased. Incidence was higher among patients who are Black compared to patients who are White (IRR: 1.71, 95% CI: 1.48-1.98,
Conclusion UNASSIGNED
PB incidence is highest among children and patients who are Black, and there may be a potential interaction between these factors. Survival is worse among males, young children, and elderly adults, and those who received no surgery. Comprehensive, population-based statistics provide critical information on PB characteristics that could be useful in impacting patient care and prognosis.

Identifiants

pubmed: 35371520
doi: 10.1093/nop/npac009
pii: npac009
pmc: PMC8965073
doi:

Types de publication

Journal Article

Langues

eng

Pagination

149-157

Informations de copyright

Published by Oxford University Press 2022.

Références

Neurosurgery. 1995 Sep;37(3):383-90; discussion 390-1
pubmed: 7501100
World Neurosurg. 2014 Dec;82(6):1232-41
pubmed: 25045788
Cancer. 2012 Jan 1;118(1):173-9
pubmed: 21717450
World Neurosurg. 2018 Oct;118:e871-e879
pubmed: 30031180
Acta Neuropathol. 2020 Feb;139(2):223-241
pubmed: 31820118
Cell Mol Life Sci. 2015 Sep;72(17):3323-42
pubmed: 25985759
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1389-1397
pubmed: 32349967
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
Neurosurgery. 2020 May 1;86(5):E426-E435
pubmed: 32110805
Neurosurgery. 2017 Jul 1;81(1):120-128
pubmed: 28327927
Acta Neuropathol. 2020 Feb;139(2):243-257
pubmed: 31768671

Auteurs

Kaitlyn Greppin (K)

Hathaway Brown School, Science Research & Engineering Program, Shaker Heights, Ohio, USA.

Gino Cioffi (G)

Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA.

Kristin A Waite (KA)

Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA.

Quinn T Ostrom (QT)

Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.

Daniel Landi (D)

The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.

Kailey Takaoka (K)

Hathaway Brown School, Science Research & Engineering Program, Shaker Heights, Ohio, USA.

Carol Kruchko (C)

Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.

Jill S Barnholtz-Sloan (JS)

Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, Maryland, USA.

Classifications MeSH